{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:53:30Z","timestamp":1787961210128,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI120855"],"award-info":[{"award-number":["K23AI120855"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["K23HD105495"],"award-info":[{"award-number":["K23HD105495"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s10461-024-04454-4","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T12:03:07Z","timestamp":1722427387000},"page":"3719-3732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["\u201cNo One Needs to be Forced\u201d: Qualitative Insights on Competing Priorities between Antiretroviral Therapy and Reproductive Health Planning during the Dolutegravir Rollout"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0845-2795","authenticated-orcid":false,"given":"Mehar","family":"Maju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukri A.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy","family":"Maina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie G","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Komanapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Humphrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy","family":"Changwony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Jakait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Wools-Kaloustian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9893-5856","authenticated-orcid":false,"given":"Rena C.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"4454_CR1","doi-asserted-by":"publisher","first-page":"100573","DOI":"10.1016\/j.eclinm.2020.100573","volume":"28","author":"S Kanters","year":"2020","unstructured":"Kanters S, Vitoria M, Zoratti M, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400\u00a0mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. EClinicalMedicine. 2020;28:100573. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100573","journal-title":"EClinicalMedicine"},{"issue":"Suppl 2","key":"4454_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10461-021-03475-7","volume":"25","author":"CE Rodriguez-Diaz","year":"2021","unstructured":"Rodriguez-Diaz CE, Davis W, Ellis MV, et al. Disrupting the systems: opportunities to enhance Methodological approaches to address Socio-Structural determinants of HIV and End the Epidemic through Effective Community Engagement. AIDS Behav. 2021;25(Suppl 2):225\u201331. https:\/\/doi.org\/10.1007\/s10461-021-03475-7","journal-title":"AIDS Behav"},{"issue":"9","key":"4454_CR3","doi-asserted-by":"publisher","first-page":"e0222229","DOI":"10.1371\/journal.pone.0222229","volume":"14","author":"M Cruciani","year":"2019","unstructured":"Cruciani M, Parisi SG. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: a systematic review and meta-analysis. PLoS ONE. 2019;14(9):e0222229. https:\/\/doi.org\/10.1371\/journal.pone.0222229","journal-title":"PLoS ONE"},{"issue":"9","key":"4454_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1056\/NEJMoa1904340","volume":"381","author":"C Kouanfack","year":"2019","unstructured":"NAMSAL ANRS 12313 Study Group, Kouanfack C, Mpoudi-Etame M, et al. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. N Engl J Med. 2019;381(9):816\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1904340","journal-title":"N Engl J Med"},{"issue":"3","key":"4454_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40273-020-00987-3","volume":"39","author":"MAQ Bousmah","year":"2021","unstructured":"Bousmah MAQ, Nishimwe ML, Tovar-Sanchez T, et al. Cost-utility analysis of a Dolutegravir-based Versus Low-Dose Efavirenz-based regimen for the initial treatment of HIV-Infected patients in Cameroon (NAMSAL ANRS 12313 trial). PharmacoEconomics. 2021;39(3):331\u201343. https:\/\/doi.org\/10.1007\/s40273-020-00987-3","journal-title":"PharmacoEconomics"},{"key":"4454_CR6","unstructured":"(WHO) WHO. WHO recommends dolutegravir as preferred HIV treatment option in all populations. Accessed February 2. 2023. https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations"},{"issue":"9","key":"4454_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1056\/NEJMoa1905230","volume":"381","author":"R Zash","year":"2019","unstructured":"Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019;381(9):827\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1905230","journal-title":"N Engl J Med"},{"key":"4454_CR8","unstructured":"(WHO) WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Accessed February 2. 2023. https:\/\/apps.who.int\/iris\/handle\/10665\/277395"},{"key":"4454_CR9","unstructured":"MOH KM of H. Statement on the use of dolutegravir in women of child bearing age (15\u201349 yrs). Published online 2018."},{"key":"4454_CR10","unstructured":"NASCOP NA and SCProgramme. Guidelines on use of antiretroviral drugs for treating and preventing HIV infection in Kenya. Nairobi. Published online 2018."},{"key":"4454_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1186\/s12879-021-06851-9","volume":"21","author":"A Twimukye","year":"2021","unstructured":"Twimukye A, Laker M, Odongpiny EAL, et al. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda. BMC Infect Dis. 2021;21:1154.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"4454_CR12","doi-asserted-by":"publisher","first-page":"e25352","DOI":"10.1002\/jia2.25352","volume":"22","author":"LM Mofenson","year":"2019","unstructured":"Mofenson LM, Pozniak AL, Wambui J, et al. Optimizing responses to drug safety signals in pregnancy: the examples of dolutegravir and neural tube defects. J Int AIDS Soc. 2019;22(7):e25352. https:\/\/doi.org\/10.1002\/jia2.25352","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"4454_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.7326\/M21-3037","volume":"175","author":"ML Romo","year":"2022","unstructured":"Romo ML, Patel RC, Edwards JK, et al. Disparities in Dolutegravir Uptake affecting females of Reproductive Age with HIV in Low- and Middle-Income Countries after initial concerns about teratogenicity: an observational study. Ann Intern Med. 2022;175(1):84\u201394. https:\/\/doi.org\/10.7326\/M21-3037","journal-title":"Ann Intern Med"},{"key":"4454_CR14","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1186\/s12889-020-09991-w","volume":"20","author":"Y Alhassan","year":"2020","unstructured":"Alhassan Y, Twimukye A, Malaba T, et al. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda. BMC Public Health. 2020;20:1883. https:\/\/doi.org\/10.1186\/s12889-020-09991-w","journal-title":"BMC Public Health"},{"issue":"12","key":"4454_CR15","doi-asserted-by":"publisher","first-page":"e26046","DOI":"10.10002\/jia2.26046","volume":"25","author":"JM Humphrey","year":"2022","unstructured":"Humphrey JM, Omody V, Bernard C, et al. Contraception use and HIV outcomes among women initiating dolutegravir-containing antiretroviral therapy in Kenya: a retrospective cohort study. J Int AIDS Soc. 2022;25(12):e26046. https:\/\/doi.org\/10.10002\/jia2.26046","journal-title":"J Int AIDS Soc"},{"key":"4454_CR16","unstructured":"Bernard C, Humphrey J, Thorne JG et al. (2020, July 6\u201310). Chaguo Langu -- My Choice: Counseling and shared decision-making about antiretroviral therapy and reproductive health options in western Kenya [Conference presentation]. International AIDS Conference 2020, virtual. https:\/\/www.aids2020.org\/"},{"issue":"2","key":"4454_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12687-021-00543-2","volume":"13","author":"EB Felipe-Dimog","year":"2022","unstructured":"Felipe-Dimog EB, Tumulak MAJR, Laurino MY, et al. Beliefs on the causes of birth defects as perceived by mothers of children with birth defects in a tertiary care hospital in the Philippines. J Community Genet. 2022;13(2):183\u201391. https:\/\/doi.org\/10.1007\/s12687-021-00543-2","journal-title":"J Community Genet"},{"key":"4454_CR18","unstructured":"Patel R, Mehta U, Humphrey J et al. (2023, Feb 19\u201322). Dolutegravir Exposure and Congenital Anomalies in Sub-Saharan Africa [Conference presentation]. Conference on Retroviral and Opportunistic Infections (CROI) 2023, Seattle, WA. https:\/\/www.croiconference.org\/abstract\/dolutegravir-exposure-and-congenital-anomalies-in-sub-saharan-africa\/"},{"key":"4454_CR19","unstructured":"Barlow-Mosha L, Mumpe DM, Williamson D et al. (2019, March 4\u20137). Integrase Inhibitors and Neural Tube Defects [Conference presentation]. Conference on Retroviral and Opportunistic Infections (CROI) 2019, Seattle, WA. https:\/\/www.croiconference.org\/abstract\/neural-tube-defects-hiv-and-antiretrovirals-birth-defect-surveillance-uganda\/"},{"issue":"1","key":"4454_CR20","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2352-3018(20)30268-X","volume":"8","author":"GFM Pereira","year":"2021","unstructured":"Pereira GFM, Kim A, Jalil EM, et al. National Cohort Study of Dolutegravir and pregnancy outcomes in Brazil Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. Lancet HIV. 2021;8(1):e33\u201341. https:\/\/doi.org\/10.1016\/S2352-3018(20)30268-X","journal-title":"Lancet HIV"},{"issue":"9","key":"4454_CR21","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S2352-3018(23)00108-X","volume":"10","author":"AP Kourtis","year":"2023","unstructured":"Kourtis AP, Zhu W, Lampe MA, Huang YA, Hoover KW. Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008-20: a national cohort study. Lancet HIV. 2023;10(9):e588\u201396. https:\/\/doi.org\/10.1016\/S2352-3018(23)00108-X. Epub 2023 Jul 25.","journal-title":"Lancet HIV"},{"issue":"9","key":"4454_CR22","doi-asserted-by":"publisher","first-page":"ofad441","DOI":"10.1093\/ofid\/ofad441","volume":"10","author":"MM Gill","year":"2023","unstructured":"Gill MM, Khumalo P, Chouraya C, Kunene M, Dlamini F, Hoffman HJ, Scheuerle AE, Nhlabatsi B, Mngometulu W, Dlamini-Madlopha N, Mthunzi N, Mofenson L. Strengthening the evidence: similar rates of neural tube defects among deliveries regardless of maternal HIV Status and Dolutegravir exposure in Hospital Birth Surveillance in Eswatini. Open Forum Infect Dis. 2023;10(9):ofad441. https:\/\/doi.org\/10.1093\/ofid\/ofad441","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"4454_CR23","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1056\/NEJMoa1905230","volume":"381","author":"R Zash","year":"2019","unstructured":"Zash R, Holmes L, Diseko M, Jacobson DL, Brummel S, Mayondi G, Isaacson A, Davey S, Mabuta J, Mmalane M, Gaolathe T, Essex M, Lockman S, Makhema J, Shapiro RL. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019;381(9):827\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1905230. Epub 2019 Jul 22.","journal-title":"N Engl J Med"},{"issue":"3","key":"4454_CR24","doi-asserted-by":"publisher","first-page":"e0248872","DOI":"10.1371\/journal.pone.0248872","volume":"16","author":"X Yan","year":"2021","unstructured":"Yan X, Du J, Ji G. Prevalence and factors associated with fertility desire among people living with HIV: a systematic review and meta-analysis. PLoS ONE. 2021;16(3):e0248872. https:\/\/doi.org\/10.1371\/journal.pone.0248872","journal-title":"PLoS ONE"},{"key":"4454_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/HIV.S235502","volume":"12","author":"N Shrestha","year":"2020","unstructured":"Shrestha N, Pokharel R, Poudyal A, et al. Fertility Desire and its determinants among people living with HIV in Antiretroviral Therapy Clinic of Teku Hospital, Nepal. HIVAIDS Auckl NZ. 2020;12:41\u20136. https:\/\/doi.org\/10.2147\/HIV.S235502","journal-title":"HIVAIDS Auckl NZ"},{"issue":"12","key":"4454_CR26","doi-asserted-by":"publisher","first-page":"e26046","DOI":"10.1002\/jia2.26046","volume":"25","author":"JM Humphrey","year":"2022","unstructured":"Humphrey JM, Omodi V, Bernard C, Maina M, Thorne J, Mwangi A, Wools-Kaloustian K, Patel RC. Contraception use and HIV outcomes among women initiating dolutegravir-containing antiretroviral therapy in Kenya: a retrospective cohort study. J Int AIDS Soc. 2022;25(12):e26046. https:\/\/doi.org\/10.1002\/jia2.26046. PMID: 36567432; PMCID: PMC9790976.","journal-title":"J Int AIDS Soc"},{"issue":"9534","key":"4454_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(06)69158-7","volume":"368","author":"CF Gilks","year":"2006","unstructured":"Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet Lond Engl. 2006;368(9534):505\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(06)69158-7","journal-title":"Lancet Lond Engl"},{"key":"4454_CR28","doi-asserted-by":"publisher","unstructured":"Weeramanthri TS, Dawkins HJS, Baynam G, Bellgard M, Gudes O, Semmens JB. Editorial: Precision Public Health. Frontiers in Public Health. 2018. https:\/\/doi.org\/10.3389\/fpubh.2018.00121","DOI":"10.3389\/fpubh.2018.00121"},{"issue":"1","key":"4454_CR29","doi-asserted-by":"publisher","first-page":"20305","DOI":"10.7448\/IAS.18.1.20305","volume":"18","author":"BM Meier","year":"2015","unstructured":"Meier BM, Gelpi A, Kavanagh MM, Forman L, Amon JJ. Employing human rights frameworks to realize access to an HIV cure. J Int AIDS Soc. 2015;18(1):20305. https:\/\/doi.org\/10.7448\/IAS.18.1.20305","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"4454_CR30","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/09540121.2021.1948498","volume":"34","author":"P Medeiros","year":"2022","unstructured":"Medeiros P, Gupta M, Wong H, et al. Women-centred HIV care: a scoping review to understand the current state of service delivery for women living with HIV globally. AIDS Care. 2022;34(9):1083\u201393. https:\/\/doi.org\/10.1080\/09540121.2021.1948498","journal-title":"AIDS Care"},{"issue":"6","key":"4454_CR31","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.whi.2017.08.001","volume":"27","author":"N O\u2019Brien","year":"2017","unstructured":"O\u2019Brien N, Greene S, Carter A, et al. Envisioning Women-centered HIV Care: perspectives from women living with HIV in Canada. Womens Health Issues off Publ Jacobs Inst Womens Health. 2017;27(6):721\u201330. https:\/\/doi.org\/10.1016\/j.whi.2017.08.001","journal-title":"Womens Health Issues off Publ Jacobs Inst Womens Health"},{"key":"4454_CR32","unstructured":"Frontline AIDS. Women Living with HIV Unite to Challenge the World Health Organization Uganda. https:\/\/frontlineaids.org\/wp-content\/uploads\/2021\/01\/PITCH-Dolutegravir-case-study-Jul-2020.pdf"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04454-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-024-04454-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04454-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T13:13:21Z","timestamp":1728911601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-024-04454-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["4454"],"URL":"https:\/\/doi.org\/10.1007\/s10461-024-04454-4","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"20 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}